#USA #Chicago #Innovent Biologics #Mazdutide #ADA 85th

Innovent Biologics to Present R&D Findings at ADA's 85th Scientific Sessions

Innovent Biologics, a leading biopharmaceutical company, is gearing up to showcase its cutting-edge research at the highly anticipated ADA 85th Scientific Sessions in Chicago. Scheduled from June 20-23, this event promises to be a vital platform for Innovent to unveil critical advancements in its biomedicine pipeline, specifically highlighting the clinical efficacy of its innovative drug, Mazdutide.

The Spotlight on Mazdutide

Mazdutide, designated as IBI362, is a dual agonist of GLP-1R and GCGR receptors, designed to tackle type 2 diabetes and obesity with a novel approach. During the session, Innovent's inaugural Phase 3 clinical trial results—referred to as DREAMS-1—will be presented orally. This study focuses on the effects of Mazdutide on Chinese adults diagnosed with type 2 diabetes (T2D).

Presentation Details:

• - Title: Mazdutide vs. Placebo as Monotherapy in Patients with Type 2 Diabetes (DREAMS-1)
• - Abstract Number: 306-OR
• - Format: Oral Presentation
• - Time: June 23, 2025, from 14:15 PM to 14:30 PM CST
• - Presenter: Dr. Lei Qian, Innovent Biologics

Aside from the DREAMS-1 study, multiple exploratory analyses regarding Mazdutide's mechanism of action and preclinical findings for IBI3030—a PCSK9-GGG antibody-peptide conjugate—will be highlighted in poster sessions. Some key posters include:

• - Searching for Cardiovascular Solutions: A poster discussing novel approaches to cardiovascular risk markers through a new antibody-peptide conjugate will be featured.
• - Innovative Weight Management: Other vital studies will explore the combined effects of Mazdutide on liver fat accumulation compared to well-known therapies such as Semaglutide, focusing on overall metabolic health improvements.

Contributions from Innovent's Team

Dr. Lei Qian, Innovent's VP of Clinical Development, expressed great pride in being able to present the meaningful results of the DREAMS-1 trial at such a renowned gathering. He underlined the significance of the research and how it validates Mazdutide's potential as a next-generation therapeutic option meant to combat both obesity and T2D effectively.

Statement from Dr. Lei Qian

>“At Innovent, our commitment is to push the boundaries of what's possible in biomedicine. We believe Mazdutide could be instrumental in shaping the future landscape of treatment for metabolic disorders,” Dr. Qian stated.

A Comprehensive Approach to Diabetes and Obesity

Innovent's endeavors do not stop at Mazdutide. The company is involved in various clinical trials globally. Current studies include:
1. GLORY-1: Targeting individuals with overweight or obesity in China.
2. DREAMS-2: Comparing Mazdutide and Dulaglutide effectiveness in Chinese T2D patients.
3. DREAMS-3: Evaluating Mazdutide versus Semaglutide among T2D patients with obesity.
4. New plans tackling adolescent obesity and metabolic dysfunction.

With filings for the New Drug Applications (NDAs) underway in China for both weight management and T2D glycemic control, the anticipation for Mazdutide's broader accessibility continues to grow.

Innovent Biologics: Leading the Future of Biomedicine

Established in 2011, Innovent Biologics has quickly risen to prominence by developing innovative and affordable biopharmaceuticals. The company's mission revolves around advancing treatment options for hard-to-treat diseases while collaborating with over 30 global healthcare organizations, including giants like Eli Lilly. With an impressive portfolio that features 15 marketed products, ongoing trials for potential new drugs, and unwavering dedication to high standards, Innovent is poised to impact patient care significantly.

For further information on Innovent's pioneering work and to learn about their future endeavors, visit Innovent's website or follow their updates on social media.